Preliminary evidence suggests that African Americans may not respond as well to some MS treatments, although the studies are not conclusive. For instance, one study suggested a lower response rate to interferon treatments. Thankfully, another study suggested very good responses to Tysabri. My general approach to treating African Americans with MS is to monitor their response to treatment very closely and escalate to highly active treatments (Tysabri, Rituximab) earlier than in typical caucasian patients. Future determination of genetic/ethnic differences in response to therapy will require large community based research populations currently being assembled to answer these questions. Stay tuned for more information in the next year as research projects sponsored by the Accelerated Cure Project begin enrolling patients.